- Signing completed for a strategic cooperation agreement between Evonik and Marubi
- Consumers benefit from complementary capabilities spanning raw materials, research, development and production
- Strengthening mutual cooperation to create more high-performing and sustainable products for the cosmetics industry in China
Evonik and Guangdong Marubi Biotechnology Co., Ltd. (“Marubi”) have entered into a cooperation agreement with signing taking place on July 6, 2023 in Shanghai. The partnership will enable consumers in the local cosmetics industry to benefit from both companies’ complementary capabilities in raw materials, research, development and production. Furthermore, the two organizations will exchange information on diverse topics including ingredient application and development, formulation, and studies on cosmetic market trends. Evonik and Marubi will jointly promote the development and continuous upgrade of China's beauty industry.
“Working closely with customers who share a similar vision is important for us, especially in China, where the cosmetics market is booming," said Yann d’Hervé, head of the business line Care Solutions at Evonik, “we look forward to joining hands with Marubi to create more high-performing and sustainable products and unique experiences for consumers.”
Founded in 2002, Marubi is a large-scale skin care company that engages in research, development, production, sales, training and service of eyecare and anti-aging facial skin care through science and technology. As an industry leader in China, the company combines independent innovation with open innovation, backed by extensive global technical resources, and supports a close collaboration among the industry, university, clinic, research institute and testing authority.
Dr. Chaowan Guo, Marubi’s vice general manager of R&D, said: “We are delighted and honored to enter into this strategic cooperation with Evonik. We are convinced that the deeper exchange on raw materials, formulations and market trends will lead to mutual benefits, supporting our commitment to the high-quality development of the industry, as well as our goals towards a broader international expansion.”
Evonik and Marubi have been working together for nearly two decades. To date, more than twenty products from Evonik, including a sustainable portfolio produced from natural sources and green chemistry processes, are featured in a variety of Marubi’s products and bestsellers. The two companies also maintain close communication to anticipate the latest market trends and concepts.
As the preferred sustainable specialties partner for the personal care industry, Evonik Care Solutions is guided by a Vision that puts sustainability, innovation and collaboration at its core. It also plays a critical role in the continued portfolio shift of Evonik’s life sciences division, Nutrition & Care, to System Solutions. The division aims to increase its share of System Solutions from 20 percent today to more than 50 percent by 2030.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.